Hemodynamic-guided Management Of Heart Failure Patients With Implantable Pulmonary Pressure Monitoring: A Single Center Experience.

Introduction Previous studies have proven that the use of implantable pulmonary artery pressure(iPAP) monitoring reduces hospitalization in patients with Heart Failure NYHA class III and aids hemodynamic-guided management to improve outcomes. Objective To characterize our Heart Failure population with iPAP monitoring and describe outcomes. Methods We collected data from all the patients that have gone through implantation of pulmonary artery monitoring device followed in our Heart Failure Clinic. The information was collected for the twelve months prior to and after implantation. Results The study included 20 patients, 17/20 (85%) are male. Baseline characteristics are described in table 1. 80% of the patients achieved the optimal goal of diastolic PAP. Mean number of hospitalizations prior implantation was 2 vs 0.15 post-implantation p=0.0001. The Median follow-up was 8 months (IQR 7). No complications were noted. Conclusion We have established a successful program of iPAP remote monitoring devices for hemodynamic-guided management of patients with HF regardless of LVEF with a very significant reduction in hospitalizations after implantation and without complications. Increased utilization of the device should be considered. Previous studies have proven that the use of implantable pulmonary artery pressure(iPAP) monitoring reduces hospitalization in patients with Heart Failure NYHA class III and aids hemodynamic-guided management to improve outcomes. To characterize our Heart Failure population with iPAP monitoring and describe outcomes. We collected data from all the patients that have gone through implantation of pulmonary artery monitoring device followed in our Heart Failure Clinic. The information was collected for the twelve months prior to and after implantation. The study included 20 patients, 17/20 (85%) are male. Baseline characteristics are described in table 1. 80% of the patients achieved the optimal goal of diastolic PAP. Mean number of hospitalizations prior implantation was 2 vs 0.15 post-implantation p=0.0001. The Median follow-up was 8 months (IQR 7). No complications were noted. We have established a successful program of iPAP remote monitoring devices for hemodynamic-guided management of patients with HF regardless of LVEF with a very significant reduction in hospitalizations after implantation and without complications. Increased utilization of the device should be considered.